Viventia Bio Inc. Expands Leadership Team, Names Erick

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Viventia Bio Inc. Expands Leadership Team, Names Erick Lucera as Chief Financial Officer and Gregory Adams, Ph.D., Chief Product Development Officer

WINNIPEG, Manitoba, June 5, 2015 (GLOBE NEWSWIRE) -- Viventia Bio Inc., a late clinical-stage company advancing a broad pipeline of novel anti-cancer agents, today announced the expansion of the Company's leadership team with the appointments of Erick Lucera to the position of Chief Financial Officer and Gregory Adams, Ph.D., to the newly created position of Chief Product Development Officer. Mr. Lucera will be responsible for all financial planning and reporting and will head investor relations and external communications activities. Dr. Adams will lead Viventia's team in advancing the company's oncology pipeline of novel Targeted Protein Therapeutics, fully biologic engineered proteins based on human antibody fragments that effectively deliver cytotoxic payloads directly to tumor cells. Viventia is anticipated to advance two lead clinical candidates, Vicinium™ and Proxinium™, into Phase 3 testing this year for bladder cancer and head & neck cancer, respectively. The Company also has an earlier-stage pipeline of de-immunized, systemic anti-cancer product candidates entering Phase 1/2 in Q1 2016. The appointments of Dr. Adams and Mr. Lucera are effective immediately, and both individuals will report to Stephen Hurly, Viventia's Chief Executive Officer.

"Viventia has attained significant momentum, with our two lead products to advance in Phase 3 clinical testing this year. I am excited that based on this progress we are able to attract Erick and Greg, as well as other highly accomplished professionals, to our growing team," commented Mr. Hurly. "Erick brings extensive financial expertise and a broad network of industry relationships, and Greg's immunology, antibody, and cancer background is ideally suited to the advancement of our discovery platform and product development pipeline."

Mr. Lucera brings to Viventia 20 years of experience in the life sciences, including 15 years on the "buy side" as a portfolio manager and analyst following the healthcare sector. Prior to joining Viventia, Mr. Lucera served as Vice President, Corporate Development at Aratana Therapeutics, where he helped the company grow its product pipeline through several acquisitions and in licensing transactions and assisted in the company' IPO process and additional financings. Prior to joining Aratana, Mr. Lucera served as Vice President and Healthcare Analyst at Eaton Vance Investment Managers. Previously, Mr. Lucera was a Portfolio Manager at Intrepid Capital, where he successfully constructed and managed a portfolio constructed across biotech, pharmaceutical, device, and service companies. Prior to that, Mr. Lucera held various leadership positions at Independence Investments, including Head of Healthcare Research. Mr. Lucera began his career as a staff auditor and accountant at PwC, the US member firm of PricewaterhouseCoopers. He holds a CPH in public health from Harvard University, and M.S.F. in quantitative finance from The Wallace E. Carroll Graduate School of Management of Boston College, an MBA from Indiana University Bloomington, and a B.S. in accounting from Lerner College of Business and Economics of University of Delaware and obtained the CPA designation in the State of Pennsylvania.

"During my career in biotech investing, I have had the opportunity to see many of today's leading firms in the earlier stages of their development," remarked Mr. Lucera. "Since my initial introduction to Viventia and subsequent due diligence, it has become very apparent to me that Viventia holds great potential and may be one of the most exciting cancer-focused, development-stage companies in the industry."

Dr. Adams brings to Viventia over 25 years of experience as an immunologist developing antibody-based agents for the treatment and detection of cancer.  He was Co-founder and CEO of computational antibody design company RAbD Biotech LLC, where he played a pivotal role in the development of lead agent RAD-003, a first-in-class biologic agent for the treatment of ovarian cancer.  Prior to this, Dr. Adams was the Director of Biological Research and Therapeutics at Fox Chase Cancer Center, where he led a laboratory group focused on developing antibodies and antibody-drug conjugates for the treatment of breast, ovarian and renal cancer. Greg was on the Scientific Advisory Board of Viventia for 12 years before joining. In addition, he has served on the Scientific Advisory Boards of a number of other antibody biotechnology companies, including Endo Pharmaceuticals, Symphogen, Avipep, AvidBiologics and YM Biosciences, and he currently serves on the Editorial Boards of Cancer Immunology Research, MAbs and Cancer Biotherapy & Radiopharmaceuticals and recently rotated off of the editorial board of Cancer Research. He also is Adjunct Associate Professor, Temple University School of Medicine. Dr. Adams received his B.A. in Biology from the University of California, Santa Cruz, and his Ph.D. in Immunology from the University of California, Davis.

"I am a firm believer in the potential of targeted protein payloads and have always been impressed with Viventia's technology," commented Dr. Adams. "From my perspective, Viventia's approach and its world-class team are uniquely positioned to lead this field forward to major advances in serving cancer patients."

About Viventia Bio

Viventia Bio is a late clinical-stage company advancing a broad pipeline of novel anti-cancer agents based on the Company's Targeted Protein Therapeutics (TPTs) platform. TPTs are fully biologic fusion constructs containing antibody fragments, a proprietary linker, and protein toxin payloads. The Company believes its platform offers significant advantages in treating cancer versus earlier technologies, including superior tumor targeting and better cancer cell-killing properties thru the utilization of protein payloads versus small molecules, as well as enhanced linker stability and more efficient manufacturing.

Viventia's lead clinical candidates, Vicinium™ and Proxinium™, are anticipated to progress in Phase 3 testing in 2015 for locoregional treatment of patients with non-muscle invasive bladder cancer (NMIBC) and squamous cell carcinoma of the head & neck (SCCHN), respectively. Earlier-stage programs are focused on de-immunized, systemic candidates, including VB6-901, indicated for solid tumors and expected to enter Phase 1 testing in the first quarter of next year, as well as additional preclinical candidates targeting solid tumors. Viventia was founded by life sciences entrepreneur and philanthropist Leslie L. Dan.

Justin Jackson, Burns McClellan, on behalf of Viventia Bio 212-213-0006, ext.327

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Clorox Boosts Payout With Steady $1.25 Dividend

Updated Category News Views 152

Quarterly Dividends: A Clorox Tradition It seems you can't talk about Clorox (NYSE: CLX) without mentioning its steadfast dedication to shareholders. Once again, this 113-year-old stalwart is back on the map with its juicy quarterly dividend—$1.25 per share, to be precise. That's scheduled to hit your account by February 12, 2027, if you're on the books by the end of...

Continue Reading
Holiday Grease Advice Shows Utility Work Up Close Today

Updated Category News Views 117

Butter and pan drippings are mundane right until they become a backed-up kitchen line on a crowded holiday afternoon. New Jersey American Water's Nov. 17, 2026 reminder is not glamorous utility news, and frankly it is not trying to be. It is a practical warning: fats, oils and grease can cool, harden and accumulate in household pipes and farther along the wastewater...

Continue Reading
MobileX's $10 Plan Puts Holiday Pressure on Wireless

Updated Category News Views 157

A sixty-dollar commitment is a small bet, but in wireless it can become a loud little nuisance for every carrier charging far more. MobileX has rolled out a Black Friday offer giving new customers 10GB of high-speed data, unlimited talk and text, and six months of service for $60 upfront. That pencils out to $10 a month, before taxes and government surcharges, and it runs...

Continue Reading
Red Cat Stock Drama: Revenue Targets and Legal Waves

Updated Category News Views 110

Red Cat's Revenue Predictions Crash and Burn Sitting there on August 6, 2026, Red Cat Holdings had everyone believing they were on a fast track to hitting a hefty revenue target: $150–$180 million for FY2026. CEO Jeffrey Thompson didn't mince words, boasting confidence like a captain before a storm. Fast forward three months, and they're waving the white flag, tossing...

Continue Reading
Snowhawk Enters Telarus as Digital Demand Gets Serious

Updated Category News Views 84

Telarus just pulled another serious capital partner into the room, and that matters more than the usual law-firm victory lap. Snowhawk Partners has invested in the technology services distributor alongside Columbia Capital, which remains a long-standing partner. Nobody disclosed a valuation, ownership percentage, financing mix, or closing date. Annoying? Sure. But the...

Continue Reading
Sola's 11-Step Push Makes Salon Ownership Less Blind

Updated Category News Views 227

A pristine studio does not pay rent by itself. That is the uncomfortable little truth sitting underneath Sola Salons’ new 11-step roadmap for beauty professionals considering salon-suite ownership. The company is telling stylists, estheticians, nail technicians, massage therapists, and other independent operators to treat the move from commission work to ownership like...

Continue Reading
CD Rates Offer Stillness as Stocks and Gold Wobble

Updated Category News Views 111

November has delivered the sort of tape that makes a supposedly diversified portfolio feel like a leaky boat. Stocks fell sharply, gold slid to a one-year low after record highs as recently as January, and Treasuries have not provided the dependable ballast many investors expected. When inflation worries and federal-debt concerns shove yields higher, bond prices can drop...

Continue Reading
ZTO's Pricing Muscle Shows Up in Third-Quarter Results

Updated Category News Views 182

Ten billion parcels can hide plenty of ugly economics, but ZTO's third quarter does not look like a volume-at-any-cost stunt. The company moved 10.241 billion parcels, up 7.0% from a year earlier, and says that outpaced the industry by 4.1 percentage points. More importantly, revenue climbed 21.0% to RMB14.36 billion while adjusted net income reached RMB2.57 billion. That...

Continue Reading
Unisys Opens Its 2027 Innovation Program Across India

Updated Category News Views 26

Talent pipelines rarely make the market’s pulse race, but they can expose whether a tech firm is still trying to build for the next turn. Unisys has opened registration for the 2027 Unisys Innovation Program, its eighteenth annual technical competition for engineering students in India. For a company selling cloud, AI, digital workplace, applications and enterprise...

Continue Reading
Wonder Create: Democratizing Restaurant Creation

Updated Category News Views 135

Breaking Down Barriers in the Restaurant Industry It's been a long time since someone truly shook up the restaurant scene like this. Wonder Create is stepping in to turn anyone with a wild food idea into a bonafide restaurateur. We're not talking about the ol' franchising route here. We're diving straight into democratizing the culinary world. You seen something this bold...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Rush to ExoraPad: The Rise of $EXP Tokens Explained

Updated Category News Views 219

Investors Flock to ExoraPad as the $EXP Token Presale Surges As the digital currency landscape evolves, many investors are seeking the next big opportunity. ExoraPad has emerged as a focal point in this space, particularly for those involved with XRP. The ongoing presale for the $EXP token has garnered immense attention, attracting numerous investors eager to secure their...

Continue Reading
Key Insights on DFDS A/S Share Transactions Involving Managers

Updated Category News Views 251

Recent Share Transactions by DFDS A/S Leadership On February 25, a significant transaction was recorded involving Claus V. Hemmingsen, the Chair of the Board of Directors for DFDS A/S, who purchased 5,000 shares of the company. This action showcases the confidence of the company’s leadership in its growth trajectory and operational strategy. Regulatory Obligations Under...

Continue Reading
First Guaranty Bancshares Reaches New Stock Milestone

Updated Category News Views 253

First Guaranty Bancshares Achieves New Milestone First Guaranty Bancshares Inc (NASDAQ: FGBI) has recently achieved a notable milestone, with its stock hitting a new 52-week high of $13.38. This impressive leap highlights a phase of robust growth for the company, reflected in the rising stock price that has been buoyed by favorable market sentiments. Over the past year,...

Continue Reading
Pho Hoa & Jazen Tea Expands Southeast with New Location

Updated Category News Views 314

Pho Hoa & Jazen Tea Expands into the Southeast Pho Hoa & Jazen Tea is excited to announce the grand opening of a new restaurant in Marietta, marking an important milestone in the brand's expansion strategy. With over 40 years dedicated to perfecting pho noodle soup, the company is eager to bring its incredible Vietnamese culinary experience to new customers. Exciting New...

Continue Reading
IDT Corporation's Commitment to Shareholders with New Dividend

Updated Category News Views 74

IDT Corporation Announces Quarterly Dividend for Shareholders IDT Corporation (NYSE: IDT), a key player in communications and payment services, has recently made waves by declaring a quarterly cash dividend of $0.05 per share. This news was shared through a regulatory filing, illustrating the company's ongoing commitment to providing value to its shareholders. Details on...

Continue Reading